Transcription poisoning by topoisomerase i is controlled by gene length, splice sites, and miR-142-3p

Cancer Research

Volumn 73, Issue 15, 2013, Pages 4830-4839

  Solier, Stephanie ^a   Ryan, Michael C ^a,c   Martin, Scott E ^b   Varma, Sudhir ^a   Kohn, Kurt W ^a   Liu, Hongfang ^a   Zeeberg, Barry R ^a   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c In Silico Solutions   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE (ATP HYDROLYSING); MICRORNA; MICRORNA 142 3P; RNA; UBIQUITIN; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HCT116; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; EXON; GENE EXPRESSION; GENE MAPPING; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INTRON; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA DEGRADATION; RNA SPLICING; UPREGULATION;

CAMPTOTHECIN; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE I; GENE EXPRESSION REGULATION; HCT116 CELLS; HUMANS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; RNA, SMALL INTERFERING; TOPOISOMERASE I INHIBITORS; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 84881452051     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3504     Document Type: Article

References (50)

1. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.
2. Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev 2009;109:2894-902.
3. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-8.
4. Ljungman M, Hanawalt PC. The anti-cancer drug camptothecin inhibits elongation but stimulates initiation of RNA polymerase II transcription. Carcinogenesis 1996;17:31-5.
5. Seiler JA, Conti C, Syed A, Aladjem MI, Pommier Y. The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses. Mol Cell Biol 2007;27:5806-18.
6. Hsiang Y-H, Lihou MG, Liu LF. Arrest of DNA replication by drugstabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989;49:5077-82.
7. Strumberg D, Pilon AA, Smith M, Hickey R, Malkas L, Pommier Y. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 50-phosphorylated DNA double-strand breaks by replication runoff. Mol Cell Biol 2000;20:3977-87.
8. Wu J, Liu LF. Processing of topoisomerase I cleavable complexes into DNA damage by transcription. Nucleic Acids Res 1997;25:4181-6.
9. Pommier Y. DNA topoisomerases and cancer. Springer-Cancer Research: New York, 2012.
10. Dexheimer TS, Kozekova A, Rizzo CJ, Stone MP, Pommier Y. The modulation of topoisomerase I-mediated DNA cleavage and the induction of DNA-topoisomerase I crosslinks by crotonaldehydederived DNA adducts. Nucleic Acids Res 2008;36:4128-36.
11. Pommier Y, Barcelo JM, Rao VA, Sordet O, Jobson AG, Thibaut L, et al. Repair of topoisomerase I-mediated DNA damage. Prog Nucleic Acid Res Mol Biol 2006;81:179-229.
12. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001;70:369-413.
13. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002;3:430-40.
14. Kretzschmar M, Meisterernst M, Roeder RG. Identification of human DNA topoisomerase I as a cofactor for activator-dependent transcription by RNA polymerase II. Proc Natl Acad Sci U S A 1993;90: 11508-12.
15. Shykind BM, Kim J, Stewart L, Champoux JJ, Sharp PA. Topoisomerase I enhances TFIID-TFIIA complex assembly during activation of transcription. Genes Dev 1997;11:397-407.
16. Rossi F, Labourier E, Forne T, Divita G, Derancourt J, Riou JF, et al. Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature 1996;381:80-2.
17. Andersen FF, Tange TO, Sinnathamby T, Olesen JR, Andersen KE, Westergaard O, et al. The RNA splicing factor ASF/SF2 inhibits human topoisomerase I mediated DNA relaxation. J Mol Biol 2002;322: 677-86.
18. Shkreta L, Froehlich U, Paquet ER, Toutant J, Elela SA, Chabot B. Anticancer drugs affect the alternative splicing of Bcl-x and other human apoptotic genes. Mol Cancer Ther 2008;7:1398-409.
19. Eisenreich A, Bogdanov VY, Zakrzewicz A, Pries A, Antoniak S, Poller W, et al. Cdc2-like kinases and DNA topoisomerase I regulate alternative splicing of tissue factor in human endothelial cells. Circ Res 2009;104:589-99.
20. Solier S, De Cian MC, Bettaieb A, Desoche L, Solary E, Corcos L. PKC zeta controls DNA topoisomerase-dependent human caspase-2 premRNA splicing. FEBS Lett 2008;582:372-8.
21. Solier S, Lansiaux A, Logette E, Wu J, Soret J, Tazi J, et al. Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. Mol Cancer Res 2004;2:53-61.
22. Soret J, Gabut M, Dupon C, Kohlhagen G, Stevenin J, Pommier Y, et al. Altered serine/arginine-rich protein phosphorylation and exonic enhancer-dependent splicing in Mammalian cells lacking topoisomerase I. Cancer Res 2003;63:8203-11.
23. Baranello L, Bertozzi D, Fogli MV, Pommier Y, Capranico G. DNA topoisomerase I inhibition by camptothecin induces escape of RNA polymerase II from promoter-proximal pause site, antisense transcription and histone acetylation at the human HIF-1alpha gene locus. Nucleic Acids Res 2010;38:159-71.
24. Solier S, Barb J, Zeeberg BR, Varma S, Ryan MC, Kohn KW, et al. Genome-wide analysis of novel splice variants induced by topoisomerase I poisoning shows preferential occurrence in genes encoding splicing factors. Cancer Res 2010;70:8055-65.
25. Huang HS, Allen JA, Mabb AM, King IF, Miriyala J, Taylor-Blake B, et al. Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature 2011;481:185-9.
26. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
27. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article3.
28. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memoryefficient alignment of short DNA sequences to the human genome. Genome Biol 2009;10:R25.
29. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497-501.
30. Zoppoli G, Solier S, ReinholdWC, Liu H, ConnellyJWJr,Monks A, et al. CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute. Oncogene 2012;31:403-18.
31. Sinha AU, Kaimal V, Chen J, Jegga AG. Dissecting microregulation of a master regulatory network. BMC Genomics 2008;9:88.
32. Zhang R, Su B. Small but influential: the role of microRNAs on gene regulatory network and 30UTR evolution. J Genet Genomics 2009; 36:1-6.
33. Kawasaki H, Taira K. MicroRNA-196 inhibits HOXB8 expression in myeloid differentiation of HL60 cells. Nucleic Acids Symp Ser (Oxf) 2004:211-2.
34. Eulalio A, Huntzinger E, Nishihara T, Rehwinkel J, Fauser M, Izaurralde E. Deadenylation is a widespread effect of miRNA regulation. RNA 2009;15:21-32.
35. He L, He X, Lowe SW, Hannon GJ. microRNAs join the p53 network- another piece in the tumour-suppression puzzle. Nat Rev Cancer 2007; 7:819-22.
36. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447:1130-4.
37. Cannell IG, Kong YW, Johnston SJ, Chen ML, Collins HM, Dobbyn HC, et al. p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependentDNA replication. Proc Natl Acad Sci U S A 2010;107:5375-80.
38. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, Schepeler T, et al. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 2008;68:10094-104.
39. Georges SA, Biery MC, Kim SY, Schelter JM, Guo J, Chang AN, et al. Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. Cancer Res 2008;68: 10105-12.
40. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature 2009;460: 529-33.
41. Chaudhry MA. Real-time PCR analysis of micro-RNA expression in ionizing radiation-treated cells. Cancer Biother Radiopharm 2009; 24:49-56.
42. Chaudhry MA, Sachdeva H, Omaruddin RA. Radiation-induced micro- RNA modulation in glioblastoma cells differing in DNA-repair pathways. DNA Cell Biol 2010;29:553-61.
43. Kann HE Jr, Kohn KW. Effects of deoxyribonucleic acid-reactive drugs on ribonucleic acid synthesis in leukemia L1210 cells. Mol Pharmacol 1972;8:551-60.
44. Desai SD, Zhang H, Rodriguez-Bauman A, Yang JM, Wu X, Gounder MK, et al. Transcription-dependent degradation of topoisomerase IDNA covalent complexes. Mol Cell Biol 2003;23:2341-50.
45. Khobta A, Ferri F, Lotito L, Montecucco A, Rossi R, Capranico G. Early effects of topoisomerase I inhibition on RNA polymerase II along transcribed genes in human cells. J Mol Biol 2006;357:127-38.
46. Sordet O, Larochelle S, Nicolas E, Stevens EV, Zhang C, Shokat KM, et al. Hyperphosphorylation of RNA polymerase II in response to topoisomerase I cleavage complexes and its association with transcription- and BRCA1-dependent degradation of topoisomerase I. J Mol Biol 2008;381:540-9.
47. Solier S, Logette E, Desoche L, Solary E, Corcos L. Nonsense-mediated mRNA decay among human caspases: the caspase-2S putative protein is encoded by an extremely short-lived mRNA. Cell DeathDiffer 2005;12:687-9.
48. Zhou Y, Gwadry FG, Reinhold WC, Miller LD, Smith LH, Scherf U, et al. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res 2002;62:1688-95.
49. Lotito L, Russo A, Bueno S, Chillemi G, Fogli MV, Capranico G. A specific transcriptional response of yeast cells to camptothecin dependent on the Swi4 and Mbp1 factors. Eur J Pharmacol 2009; 603:29-36.
50. Zhang HF, Tomida A, Koshimizu R, Ogiso Y, Lei S, Tsuruo T. Cullin 3 promotes proteasomal degradation of the topoisomerase I-DNA covalent complex. Cancer Res 2004;64:1114-21.